Although checkpoint blockade immunotherapies have advanced rapidly in the treatment paradigm for patients with non–small cell lung cancer, interest in developing targeted therapies for this malignancy has remained high.
Original Article: Interest Builds in Targeting MET Mutations in Non-Small Cell Lung Cancer